Abstract: A device for obtaining physiological information of a medical patient and wirelessly transmitting the obtained physiological information to a wireless receiver. The device can include a blood pressure device that can be coupled to a medical patient and a wireless transceiver electrically coupled with the blood pressure device. The wireless transceiver can wirelessly transmit blood pressure data received by the blood pressure device and physiological data received from one or more physiological sensors coupled to the blood pressure device.

Abstract: The invention features ITF expression vectors and methods of producing ITF.

Abstract: The present invention features methods of treating a patient having an epithelial lesion or disorder of impaired mucin function. The present invention further features methods of treating pain associated with epithelial lesions and disorders of impaired mucin function. Epithelial lesions and disorders of impaired mucin function can be treated using a pharmaceutical composition containing mucin glycoproteins in combination with therapeutic agents, e.g., trefoil polypeptides.

Abstract: The invention features compositions and methods for treating and preventing epithelial lesions and disorders by administering trefoil domain-containing polypeptides and trefoil peptide fragments. The trefoil domain-containing polypeptides and trefoil peptide fragments can be administered alone or in combination with other therapeutic agents.

Abstract: This invention features methods for preparing and using asialo-interferons, including asialo-interferon-&agr;, asialo-interferon-&agr;2a, asialo-interferon-&agr;2b, asialo-interferon-&bgr;, asialo-interferon-&bgr;1a, asialo-interferon-&bgr;1b and asialo-interferon-&ggr;, for treating liver cancer. Asialo-interferon therapy may be used alone or in combination with other antineoplastic therapies.

Abstract: The present invention features methods for preparing and using modified asialo-interferons for the treatment of hepatic diseases. Asialo-interferons are modified by the addition of water soluble polymers including, for example, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), poly (alkylene oxides), such as poly (propylene glycol) (PPG), polytrimethylene glycol (PTG), and poly(oxyethylated polyols), such as poly(oxyethylated sorbitol), poly(oxyethylated glycerol, and poly(oxyethylated glucose). The asialo-interferons that may be modified and used for the treatment of hepatic diseases include, for example, asialo-interferon -&agr;, -&bgr;, and -&ggr;.